Purpose: This systematic review and meta-analysis aimed to investigate the clinical outcomes of xenogeneic bone blocks (XBB) used for lateral ridge augmentation, specifically focusing on bone gain, graft survival, and implant survival.
Materials And Methods: Data search was conducted in Pubmed, Embase, and ClinicalTrial.gov for randomized controlled trials (RCTs), and prospective cohort studies up to March 1, 2024. Horizontal bone gain (HBG), horizontal bone resorption (HBR), graft survival rate, and implant survival rate were analyzed. Cochrane Risk of Bias Tool 2 and Newcastle-Ottawa Scale were applied to assess the quality and risks of the included studies.
Results: Four RCTs and five prospective cohortstudies, comprised 120 graft sites and 141 implants in total were included for the meta- analysis. Non-comparative analysis resulted in a weighted mean horizontal bone gain (HBG) of 4.38 mm and horizontal bone resorption (HBR) of 0.85 mm. Comparative analysis with data from 4 RCTs that paired xenogeneic bone block (XBB) with autogenous bone block (ABB) exhibited a statistically significant greater HBG in XBB, with a mean difference of 0.72mm (95% CI=0.067 to 1.382, p=0.031, I2=28.2%). The weighted graft survival rate for XBB was 91.3% (95% CI = 76.6% to 97.1%, I2 = 58.0 %), and the weighted implant survival rate was 84.3% (95% CI = 72.6% to 91.6%, I2 = 31.6 %). Histologically, mean percentage of mineralized vital bone in XBB ranged from 11.6% to 29.8%, and the resorption rate ranged from 7.3% to 21%.
Conclusion: The utilization of xenogeneic bone block for lateral ridge augmentation demonstrates an acceptable survival rate and yields an adequate volume of bone for subsequent implant therapy. Nonetheless, the survival rate of implants placed in ridges augmented with xenogeneic blocks is less favorable when compared to those augmented with autogenous block grafts.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.11607/jomi.11048 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Finding Value in Pediatric Liver Transplantation: When Does Volume Matter?
J Surg Res
January 2025
Department of Pediatric Surgery, Phoenix Children's Hospital, Phoenix, Arizona. Electronic address:
Introduction: Pediatric liver transplantation provides substantial survival benefit. An emphasis on value-based practices has become a central theme in many surgical fields, but have not been well-studied in pediatric transplantation. Given an increasing focus on optimizing outcomes while containing costs, defining value in pediatric liver transplantation warrants investigation.
View Article and Find Full Text PDFEffectiveness of regorafenib in second-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Medicine (Baltimore)
January 2025
Department of Hepatobiliary Surgery, The Third Central Hospital of Tianjin, Tianjin, China.
Background: In patients with advanced hepatocellular carcinoma (HCC) following sorafenib failure, regorafenib has been used as an initial second-line drug. It is unclear the real efficacy and safety of sorafenib-regorafenib sequential therapy compared to placebo or other treatment (cabozantinib or nivolumab or placebo) in advanced HCC.
Methods: Four electronic databases (PubMed, Embase, Web of Science, and Ovid) were systematically searched for eligible articles from their inception to July, 2024.
The choice of adjuvant radiotherapy in pancreatic cancer patients after up-front radical surgery.
PLoS One
January 2025
Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
Background: The role of adjuvant radiotherapy in pancreatic cancer following radical surgery remains a subject of of controversy. This study aimed to more accurately screen pancreatic patients who benefit from adjuvant radiotherapy.
Methods: Clinicopathologic characteristics of patients with resectable pancreatic cancer were collected from the Surveillance, Epidemiology, and End Results (SEER) database (2004-2015).
Incidence and predictors of mortality among HIV positive children on anti-retroviral therapy in the selected health facilities of West Wollega Zone, Western Ethiopia: Retrospective cohort study.
PLoS One
January 2025
Departments of Public Health, Institute of Health Sciences, Wollega University, Ethiopia.
Introduction: The mortality rate among Human immunodeficiency Virus (HIV) who have started antiretroviral therapy (ART) continues to be increased in resource-limited countries, despite a decline in developed nations. Furthermore, research within this age group is limited and has not previously been conducted in the study area. Consequently, this study aimed to determine the incidence of mortality and its predictors among HIV-positive children who have been receiving ART at public health facilities in West Wollega.
View Article and Find Full Text PDFParametric modeling of under-5 children survival among 30 African countries: Lognormal accelerated failure time gamma shared frailty model.
PLoS One
January 2025
Department of Environmental and Occupational Health and Safety, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia.
Background: Under-five mortality continues to be a serious public health concern in low-and middle-income countries, particularly in Africa. This study investigates the probability of under-five survival and its predictors of mortality in the African continent using a recent demographic health survey from 2014-2022.
Methods: This study utilized recent Demographic and Health Survey data from 30 African countries, encompassing 226,862 live births.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!